The evolving role of DICOM in digital pathology
This is a summary of the full-text article by Cornish et al., which can be accessed at
https://www.sciencedirect.com/science/article/pii/S2153353926001161
Published in JPI on 30 April 2026
Overview
- Digital Imaging and Communications in Medicine (DICOM) is a global standard that is used for interpreting digital images without the need to use proprietary vendor-specific images
- More than 90% of the medical images in radiology are exchanged using DICOM
- The need for DICOM use in digital pathology has increased due to the requirement for a more streamlined vendor-neutral data exchange
- In 2024, Leica Biosystems, through Aperio GT 450 DX scanner, became the first company to get FDA approval to produce native DICOM images
- A DICOM whole slide image (WSI) is stored as a pyramidical structure
- A WSI is stored in a multilevel, multiresolution form
- Each level’s image resolution is divided into sub-regions or tiles
- Each tile represents an image frame
- Each frame/tile can be retrieved by the user, enabling efficient navigation
Increased Interoperability
To encourage adoption and interoperability, Leica Biosystems has chosen not to enforce restrictions on its patented DICOM compliant imaging module.
Enhanced Collaboration
DICOM implementation allows for greater collaboration among pathologists.
Embeds with Computational Pathology
DICOM facilitates AI annotation and supports digital pathology and computation pathology integration.
Challenges
- A survey study reported only 11% (16/137) users utilizing DICOM, suggesting low adoption of this file format.
- Only a handful of scanners supporting native DICOM output.
Opportunities
- Growing pathologist interest in implementing this new technology for ease of information exchange.
- Uptick in approval of DICOM-compliant digital pathology scanners.
Leica Biosystems is helping shape the official policy for DICOM implementation by being a part of working groups, connectathons, and conferences.
Learn More Download Article (PDF)
Concerted effort is needed by the stakeholders for increased awareness of DICOM in digital pathology, which may lead to accurate and quicker case diagnosis turnaround time, thereby improving patient care.
발표자 소개
Shubham Dayal is a Senior Medical Writer at Leica Biosystems and has over 10 years of experience in regulatory/preclinical/clinical writing for studies that are at different stages of the product lifecycle. Shubham has a PhD in Cell and Molecular Biology from the University of Toledo and a Master's in Regulatory Affairs from Northeastern University and has co-authored multiple peer-reviewed articles and poster presentations. He is an active member of the Regulatory Affairs Professional Society and American Medical Writers Association and holds certifications related to scientific writing. In his current role, Shubham's goal is to create awareness for our customers in ways that can advance scientific communication and ultimately improve patient outcomes.
라이카 바이오시스템즈 Knowledge Pathway 콘텐츠는 에서 이용할 수 있는 라이카 바이오시스템즈 웹사이트 이용 약관의 적용을 받습니다. 법적고지. 라이카 바이오시스템즈 웨비나, 교육 프레젠테이션 및 관련 자료는 특별 주제 관련 일반 정보를 제공하지만 의료, 규정 또는 법률 상담으로 제공되지 않으며 해석되어서는 안 됩니다. 관점과 의견은 발표자/저자의 개인 관점과 의견이며 라이카 바이오시스템즈, 그 직원 또는 대행사의 관점이나 의견을 나타내거나 반영하지 않습니다. 제3자 자원 또는 콘텐츠에 대한 액세스를 제공하는 콘텐츠에 포함된 모든 링크는 오직 편의를 위해 제공됩니다.
모든 제품 사용에 다양한 제품 및 장치의 제품 정보 가이드, 부속 문서 및 작동 설명서를 참조해야 합니다.
Copyright © 2026 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.